Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Gedatolisib by Celcuity for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Gedatolisib is under clinical development by Celcuity and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Gedatolisib by Celcuity for Endometrial Cancer: Likelihood of Approval
Gedatolisib is under clinical development by Celcuity and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I...
Gedatolisib by Celcuity for Pancreatic Cancer: Likelihood of Approval
Gedatolisib is under clinical development by Celcuity and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...
Gedatolisib by Celcuity for Cervical Cancer: Likelihood of Approval
Gedatolisib is under clinical development by Celcuity and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
Gedatolisib by Celcuity for Ovarian Cancer: Likelihood of Approval
Gedatolisib is under clinical development by Celcuity and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
Gedatolisib by Celcuity for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Gedatolisib is under clinical development by Celcuity and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...
Risk adjusted net present value: What is the current valuation of Celcuity's Gedatolisib?
Gedatolisib is a small molecule commercialized by Celcuity, with a leading Phase III program in Human Epidermal Growth Factor Receptor...
Risk adjusted net present value: What is the current valuation of Celcuity's Gedatolisib?
Gedatolisib is a small molecule commercialized by Celcuity, with a leading Phase II program in Human Epidermal Growth Factor Receptor...